{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:09:33Z","timestamp":1778101773703,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Start-up Fund for Scientific Research of Fujian Medical University","award":["2017XQ1206"],"award-info":[{"award-number":["2017XQ1206"]}]},{"name":"Fuzhou Science and Technology Project Funds","award":["2018-S-105-2"],"award-info":[{"award-number":["2018-S-105-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Controlled studies and observational studies have shown that sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for the survival of patients with heart failure (HF). However, it is unclear whether SGLT-2i can provide benefit in patients with other cardiovascular diseases. Here, we conducted a systematic review and meta-analysis to determine the outcomes of cardiovascular, renal, and safety outcomes of SGLT-2i administration in patients with cardiovascular diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, EMBASE, Cochrane Library, Web of Science databases, and ClinicalTrials.gov databases for randomised controlled trials written in English from inception until November 1, 2020. Two reviewers independently identified randomised controlled trials comparing the effects of SGLT-2i in patients with cardiovascular disease with or without diabetes. Primary outcomes were cardiovascular outcomes and renal outcomes. Secondary outcomes were safety outcomes, including adverse endocrine outcomes and adverse infection outcomes. The effects of SGLT-2i were evaluated using RevMan5.3 software. The Cochrane risk of bias tool was used to assess study quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 10 randomised controlled trials (25,108 patients in the SGLT-2i group and 18,574 patients in the placebo group). Meta-analysis revealed that SGLT-2i treatment significantly reduced all-cause mortality, cardiovascular mortality, and hospitalisation for heart failure (HHF) in patients with cardiovascular disease (all-cause mortality relative risk [RR]: 0.86; 95% confidence interval [CI] 0.81\u20130.91;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%; cardiovascular mortality RR: 0.85; 95% CI 0.79\u20130.92;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200926%; HHF RR: 0.69; 95% CI 0.64\u20130.81;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%). In patients with HF, mortality and HHF after SGLT-2i treatment for HF with reduced ejection fraction were significantly reduced, whereas HF with preserved ejection fraction did not differ compared with placebo treatment. Moreover, SGLT-2i induced a lower incidence of renal damage and myocardial infarction than the placebo group; however, the risk of infection, amputation, volume depletion, and diabetic ketoacidosis was higher.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SGLT-2i had significant clinical effects on cardiovascular outcomes and significantly influenced acute kidney injury. The effects of SGLT-2i on cardiovascular disease were independent of diabetic status. Sotagliflozin could have advantages over other SGLT-2i in lowering HHF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-021-01272-z","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T11:04:54Z","timestamp":1619089494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of sodium\u2010glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta\u2010analysis of randomized controlled trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Caiyun","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meimei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingqun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2037-4208","authenticated-orcid":false,"given":"Hengfen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"Suppl 2","key":"1272_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/PL00002934","volume":"44","author":"NJ Morrish","year":"2001","unstructured":"Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl 2):14\u201321.","journal-title":"Diabetologia"},{"issue":"9","key":"1272_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"KI Birkeland","year":"2017","unstructured":"Birkeland KI, J\u00f8rgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nystr\u00f6m T, Eriksson JW, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"1272_CR3","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"1272_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/DMSO.S90662","volume":"8","author":"J Seufert","year":"2015","unstructured":"Seufert J. SGLT2 inhibitors\u2014an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes Targets Ther. 2015;8:543\u201354.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"1","key":"1272_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","volume":"17","author":"S Lahnwong","year":"2018","unstructured":"Lahnwong S, Chattipakorn SC, Chattipakorn N. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 2018;17(1):101.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1272_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","volume":"18","author":"Y Fei","year":"2019","unstructured":"Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18(1):112.","journal-title":"Cardiovasc Diabetol"},{"key":"1272_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2020","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2020;6:148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"1272_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119\u201329.","journal-title":"Circulation"},{"issue":"9","key":"1272_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1272_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12933-016-0419-0","volume":"15","author":"JS Singh","year":"2016","unstructured":"Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, Pearson ER, Struthers AD, Lang CC. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016;15:97.","journal-title":"Cardiovasc Diabetol"},{"key":"1272_CR11","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"1272_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1272_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"1272_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jdiacomp.2017.02.001","volume":"31","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Gause-Nilsson I, Xu J, Sonesson C, Johnsson E. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. J Diabetes Complicat. 2017;31(7):1215\u201321.","journal-title":"J Diabetes Complicat"},{"issue":"24","key":"1272_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"22","key":"1272_CR16","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","volume":"139","author":"RHM Furtado","year":"2019","unstructured":"Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation. 2019;139(22):2516\u201327.","journal-title":"Circulation"},{"issue":"21","key":"1272_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"18","key":"1272_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463\u201376.","journal-title":"Circulation"},{"key":"1272_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2020;384:117\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"1272_CR20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"15","key":"1272_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"22","key":"1272_CR22","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528\u201336.","journal-title":"Circulation"},{"issue":"23","key":"1272_CR23","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","volume":"142","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142(23):2205\u201315.","journal-title":"Circulation"},{"issue":"11","key":"1272_CR24","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.amjcard.2016.08.061","volume":"118","author":"H Tang","year":"2016","unstructured":"Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am J Cardiol. 2016;118(11):1774\u201380.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1272_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","volume":"54","author":"M Monami","year":"2017","unstructured":"Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(1):19\u201336.","journal-title":"Acta Diabetol"},{"key":"1272_CR26","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/dom.14286","volume":"23","author":"GA Silverii","year":"2020","unstructured":"Silverii GA, Monami M, Mannucci E. Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;23:1052\u20136.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"1272_CR27","doi-asserted-by":"crossref","first-page":"e007165","DOI":"10.1161\/JAHA.117.007165","volume":"7","author":"XL Zhang","year":"2018","unstructured":"Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, Xu B. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7(2):e007165.","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"1272_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12933-020-01067-8","volume":"19","author":"M Castellana","year":"2020","unstructured":"Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19(1):87.","journal-title":"Cardiovasc Diabetol"},{"issue":"10166","key":"1272_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"6","key":"1272_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.clinthera.2015.02.016","volume":"37","author":"CV Desouza","year":"2015","unstructured":"Desouza CV, Gupta N, Patel A. Cardiometabolic effects of a new class of antidiabetic agents. Clin Ther. 2015;37(6):1178\u201394.","journal-title":"Clin Ther"},{"issue":"18","key":"1272_CR31","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","volume":"139","author":"K Kario","year":"2018","unstructured":"Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, Uchiyama K, Niijima Y, Katsuya T, Urata H, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2018;139(18):2089\u201397.","journal-title":"Circulation"},{"issue":"5","key":"1272_CR32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886\u201399.","journal-title":"Diabetologia"},{"issue":"2","key":"1272_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Investig. 2014;124(2):499\u2013508.","journal-title":"J Clin Investig"},{"issue":"3","key":"1272_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/CRD.0000000000000265","volume":"28","author":"AH Malik","year":"2020","unstructured":"Malik AH, Yandrapalli S, Goldberg M, Jain D, Frishman WH, Aronow WS. Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis of randomized controlled trials. Cardiol Rev. 2020;28(3):116\u201324.","journal-title":"Cardiol Rev"},{"issue":"1","key":"1272_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jcjd.2019.09.004","volume":"44","author":"VC Woo","year":"2020","unstructured":"Woo VC. Cardiovascular effects of sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes. Can J Diabetes. 2020;44(1):61\u20137.","journal-title":"Can J Diabetes"},{"issue":"1","key":"1272_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-020-01163-9","volume":"19","author":"F Giorgino","year":"2020","unstructured":"Giorgino F, Vora J, Fenici P, Solini A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc Diabetol. 2020;19(1):196.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1272_CR37","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237\u201350.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"1272_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-020-01010-x","volume":"19","author":"D Giugliano","year":"2020","unstructured":"Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Garofalo C, Chiodini P, Ceriello A, Esposito K. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovasc Diabetol. 2020;19(1):35.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1272_CR39","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/dom.13299","volume":"20","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, J\u00f8rgensen ME, Wittbrodt ET, et al. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study. Diabetes Obes Metab. 2018;20(8):1983\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"1272_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","volume":"150","author":"B Sinha","year":"2019","unstructured":"Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8\u201316.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1272_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci. 2019;4(1):15\u201326.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"1272_CR42","first-page":"e32","volume":"24","author":"P Farahani","year":"2017","unstructured":"Farahani P. Non-severe hypoglycemia risk difference between sulfonylurea and sodium-glucose cotransporter-2 inhibitors (SGLT2-I) as an add-on to metformin in randomized controlled trials. J Popul Ther Clin Pharmacol. 2017;24(2):e32\u201340.","journal-title":"J Popul Ther Clin Pharmacol."},{"issue":"2","key":"1272_CR43","doi-asserted-by":"publisher","first-page":"e001856","DOI":"10.1136\/bmjdrc-2020-001856","volume":"8","author":"T Horii","year":"2020","unstructured":"Horii T, Oikawa Y, Kunisada N, Shimada A, Atsuda K. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Res Care. 2020;8(2):e001856.","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"23","key":"1272_CR44","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376(23):2300\u20132.","journal-title":"N Engl J Med"},{"issue":"6","key":"1272_CR45","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.dsx.2018.06.003","volume":"12","author":"V Tsimihodimos","year":"2018","unstructured":"Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr. 2018;12(6):1117\u201323.","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"1272_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/00325481.2019.1549459","volume":"131","author":"MS Kelly","year":"2019","unstructured":"Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019;131(1):31\u201342.","journal-title":"Postgrad Med"},{"issue":"11","key":"1272_CR47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1272_CR48","first-page":"46","volume":"13","author":"J Sung","year":"2018","unstructured":"Sung J, Padmanabhan S, Gurung S, Inglis S, Vicaretti M, Begg L, Cheung NW, Girgis CM. SGLT2 inhibitors and amputation risk: real-world data from a diabetes foot wound clinic. J Clin Transl Endocrinol. 2018;13:46\u20137.","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"1272_CR49","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41574-018-0001-9","volume":"14","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol. 2018;14(6):326\u20138.","journal-title":"Nat Rev Endocrinol"},{"key":"1272_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1574886315666200805103053","volume":"16","author":"NCC Werkman","year":"2020","unstructured":"Werkman NCC, Nielen JTH, van den Bergh JPW, Ejskjaer N, R\u00f8ikjer J, Schaper NC, Rossi B, Klungel O, Vestergaard P, de Vries F, et al. Use of sodium-glucose co-transporter-2-inhibitors (SGLT2-Is) and risk of lower limb amputation. Curr Drug Saf. 2020;16:62\u201372.","journal-title":"Curr Drug Saf"},{"issue":"1","key":"1272_CR51","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","volume":"9","author":"JR Donnan","year":"2019","unstructured":"Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, Swab M, Hache J, Curnew D, Nguyen H, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019;9(1):e022577.","journal-title":"BMJ Open."},{"issue":"3","key":"1272_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1272_CR53","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/dom.12853","volume":"19","author":"E Araki","year":"2017","unstructured":"Araki E, Onishi Y, Asano M, Kim H, Yajima T. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab. 2017;19(4):562\u201370.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1272_CR54","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","volume":"16","author":"J Menne","year":"2019","unstructured":"Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002983.","journal-title":"PLoS Med"},{"issue":"1","key":"1272_CR55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-019-0899-9","volume":"18","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Esposito K. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovasc Diabetol. 2019;18(1):94.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1272_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","volume":"18","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ. An update on the safety of SGLT2 inhibitors. Exp Opin Drug Saf. 2019;18(4):295\u2013311.","journal-title":"Exp Opin Drug Saf"},{"issue":"8","key":"1272_CR57","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/dom.13743","volume":"21","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K. Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. Diabetes Obes Metab. 2019;21(8):1790\u2013800.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1272_CR58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","volume":"143","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation. 2021;143(4):337\u201349.","journal-title":"Circulation"},{"issue":"10254","key":"1272_CR59","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"1","key":"1272_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-020-01042-3","volume":"19","author":"IC Hwang","year":"2020","unstructured":"Hwang IC, Cho GY, Yoon YE, Park JJ, Park JB, Lee SP, Kim HK, Kim YJ, Sohn DW. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol. 2020;19(1):69.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1272_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1079\/BJN2002763","volume":"89","author":"IS Wood","year":"2003","unstructured":"Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89(1):3\u20139.","journal-title":"Br J Nutr"},{"issue":"2","key":"1272_CR62","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D\u2019Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90(2):339\u201346.","journal-title":"J Cell Biochem."},{"key":"1272_CR63","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.","journal-title":"BMJ"},{"issue":"1","key":"1272_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12933-020-01034-3","volume":"19","author":"L Ludwig","year":"2020","unstructured":"Ludwig L, Darmon P, Guerci B. Computing and interpreting the number needed to treat for cardiovascular outcomes trials: perspective on GLP-1 RA and SGLT-2i therapies. Cardiovasc Diabetol. 2020;19(1):65.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01272-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T00:24:06Z","timestamp":1671927846000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01272-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01272-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-154500\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}